Thyroid disease in the time of COVID-19

被引：0
作者：
Dorota Dworakowska
Ashley B. Grossman
机构：
[1] Medical University of Gdansk,Departament of Hypertension and Diabetes
[2] Kings College London,Guys Richard Dimbleby Department of Cancer Research
[3] London International Clinic,Centre for Endocrinology, Barts and the London School of Medicine
[4] Queen Mary University of London,OCDEM
[5] University of Oxford,undefined
来源：
Endocrine | 2020年 / 68卷
关键词：
Thyroid; COVID-19; Thyroid autoimmune disease; AITD;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The novel coronavirus disease COVID-19 is produced by SARS-CoV-2. WHO has declared COVID-19 as a public health emergency, with the most susceptible populations (requiring ventilation) being the elderly, pregnant women and people with associated co-morbidities including heart failure, uncontrolled diabetes, chronic obstructive pulmonary disease, asthma and cancer. However, such general guidance does not provide information regarding COVID-19 risks in patients with suffering from pre-existing thyroid problems, and furthermore, we do not know whether patients with COVID-19 (symptomatic or without symptoms), who have not previously had thyroid issues develop endocrine thyroid dysfunction after infection. The European Society for Endocrinology recently published a statement on COVID-19 and endocrine diseases (Endocrine, 2020); however, thyroid diseases were not mentioned specifically. We have therefore reviewed the current literature on thyroid diseases (excluding cancer) and COVID-19, including data from the previous coronavirus pandemic caused by the SARS-associated coronavirus (SARS-CoV), a member of the same family Coronaviridae leading to severe acute respiratory syndrome (SARS). At the moment there are no data suggesting that thyroid patients are at higher risk of COVID-19, but this requites further research and data analysis.
引用
收藏
页码：471 / 474
页数：3
相关论文
共 98 条
  • [1] Guo Y(2008)Pathogenetic mechanisms of severe acute respiratory syndrome Virus Res. 133 4-12
  • [2] Korteweg C(2020)The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status Mil. Med. Res. 7 11-5
  • [3] McNutt MA(2020)Hyperglycemia and the novel Covid-19 infection: possible pathophysiologic mechanisms Med. Hypotheses 139 109699-63
  • [4] Gu J(2020)Our response to COVID-19 as endocrinologists and diabetologists JCEM 105 dgaa148-840
  • [5] Guo YR(2020)COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology Endocrine 68 2-193
  • [6] Cao QD(2015)Rheumatic and autoimmune thyroid disorders: a causal or casual relationship? Autoimmun. Rev. 14 57-234
  • [7] Hong ZS(2020)Autoimmune thyroid disorders and rheumatoid arthritis: a bidirectional interplay Autoimmun. Rev. 19 102529-630
  • [8] Tan YY(2020)Are my patients with rheumatic diseases at higher risk of COVID-19? Ann. Rheum. Dis. 79 839-202
  • [9] Chen SD(2017)Non-chemotherapy drug-induced neutropenia: key points to manage the challenges Hematology Am. Soc. Hematol. Educ. Program 2017 187-365
  • [10] Jin HJ(2003)Evaluation and observation of serum thyroid hormone and parathyroid hormone in patients with severe acute respiratory syndrome J. Chin. Antituberculous Assoc. 25 232-102
12345678910